Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
University of Arkansas - Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas START - Los Angeles, Los Angeles, California SCRI - Florida Cancer Specialists, Sarasota, Florida St. Francis Medical Center (OSF Healthcare), Peoria, Illinois Karmanos Cancer Center, Detroit, Michigan